DGP IgA

If you have unexplained digestive trouble, stubborn iron deficiency, or a close relative with celiac disease, this test looks for one of the immune signals your body makes when gluten is damaging your gut. It measures an antibody that tends to rise when the celiac immune reaction is active and fall once gluten is removed.

Think of it as a supporting player rather than the star of celiac testing. It earns its keep mainly when the standard first-line test disagrees with your symptoms. One important caution: because this is an IgA-based test, it cannot help when your body makes very little IgA overall. In that situation the IgG version of this marker, not this IgA test, is the one that fills the gap.

What This Antibody Actually Is

DGP IgA (immunoglobulin A antibodies against deamidated gliadin peptides) is a protein your immune system builds to attack a specific piece of gluten. When you eat wheat, barley, or rye, gluten is broken down into fragments called gliadin peptides. In celiac disease, an enzyme in your gut wall chemically alters these fragments, making them look more foreign to your immune system, and your body responds by producing antibodies against them.

This test measures the amount of that antibody in your blood. It does not directly measure gut damage. Instead, a high level signals that a gluten-driven immune reaction is active, which is why the marker is used as part of celiac disease testing rather than as a stand-alone diagnosis.

Celiac Disease, the Core Association

The one disease consistently tied to an abnormal result is celiac disease, an inherited condition where eating gluten damages the lining of the small intestine. A high level of this antibody, especially alongside a positive standard celiac test and gut damage seen on biopsy, supports that diagnosis in both children and adults.

Higher antibody levels tend to track more active or more severe disease. Blood tests of the IgA type are more likely to turn positive when the gut lining is badly flattened than when the damage is mild, and in treated patients, persistent antibody positivity is strongly linked to ongoing intestinal injury, with the antibody level rising in step with the degree of damage.

A positive result is not proof of celiac disease on its own. Reviews separate celiac disease from non-celiac gluten sensitivity, which produces symptoms but shows normal gut biopsy and negative standard celiac antibodies, so this antibody should never be read as a final answer without the rest of the picture.

How It Stacks Up Against the First-Line Test

The standard first blood test for celiac disease is tTG-IgA (tissue transglutaminase IgA antibodies), and across studies it outperforms this deamidated gliadin marker as an initial screen. Guideline bodies recommend starting with tTG-IgA plus a check of your total IgA, not with this antibody. Where this test can add value is in filling gaps, occasionally catching cases the first-line test misses.

Source: Agardh 2007; Lewis and Scott 2010; Sugai et al 2006.

What this means for you: this is a complementary test, not a replacement for the standard celiac screen. Its real strength shows up in specific scenarios, such as when your first-line antibody is negative but suspicion stays high. In one adult study, this family of tests flagged several biopsy-confirmed celiac patients who were negative on the two traditional markers despite having normal antibody-making ability.

Why a Positive Result Can Mislead

Here is the part that trips people up. A positive result on this test when your standard tTG-IgA is normal usually does not mean you have celiac disease. In one pediatric study, an isolated positive on the deamidated gliadin marker with a normal standard test predicted biopsy-confirmed disease only about 2 to 3 times out of 100. A larger adult referral study found the yield somewhat higher, closer to 15 or 16 out of 100, so the very low figure applies mainly to children.

This is not a contradiction so much as a lesson about how to read the marker. It is a supporting test whose meaning depends on the company it keeps. On its own it can flag immune activity that never amounts to celiac disease, but combined with a positive standard test, a compatible genetic profile, and gut damage, the same number becomes far more meaningful. Judge it as part of a panel, not in isolation.

Tracking a Gluten-Free Diet

Because this antibody depends on ongoing gluten exposure, it falls after you remove gluten and can climb again if gluten sneaks back in. Studies following people after they started a gluten-free diet saw both average antibody levels and the share of positive results drop significantly by 6 months and again by 1 year. That makes it a reasonable adjunct for monitoring, though not a precise adherence meter, since serology can still miss real ongoing gluten exposure.

When Results Can Be Misleading

A single reading can point you the wrong way for several practical reasons. The most important ones are about who you are and what you were doing before the draw.

• Low total IgA: if your body makes very little IgA overall (selective IgA deficiency), any IgA-based test, including this one, can read falsely negative. In IgA-deficient patients, IgA-based celiac antibodies were consistently negative, which is why an IgG-based test, such as IgG deamidated gliadin, is used instead. Checking your total IgA is essential for interpreting this result.
• Already off gluten: if you have cut back on gluten before testing, your level may have fallen and can hide active disease. A low or normal result in that setting reflects your diet, not the absence of celiac disease.
• Assay and cutoff differences: different labs and platforms report different numbers. The same sample can look meaningfully different from one method to the next, so comparing results across labs is unreliable.
• Very young age: in children under about 4, an isolated positive on this marker is often a passing phenomenon that does not signal true disease.

Why One Reading Is Not Enough

A single value is a snapshot, and this marker moves with your gluten exposure, your gut healing, and even which lab ran it. The trajectory tells you more than any one number. If you are newly diagnosed and starting a gluten-free diet, a falling level over months is reassuring evidence that your immune reaction is quieting. Keep in mind that antibody levels can normalize even when some gut damage persists, so serology alone does not confirm full healing. A level that stays up, or climbs, points to ongoing gluten exposure.

A practical rhythm many clinicians use: get a baseline while you are still eating gluten, so the test has something to detect, then retest around 6 months after a diagnosis and dietary change, and at least yearly thereafter. This cadence is not formally codified in major guidelines, and current monitoring guidance cautions that antibody levels can miss persistent villous atrophy, so serology supplements rather than replaces specialist follow-up. Because the antibody responds to gluten exposure, tracking your own trend on the same assay over time is more useful than any single reading.

What to Do With an Unexpected Result

If this test is positive, do not treat it as a verdict. The next steps depend on what the rest of the picture shows. The most informative companion tests are your total IgA (to rule out the deficiency that skews IgA-based results), tTG-IgA (the validated first-line screen), and often endomysial antibodies (a highly specific confirmatory test) and the IgG version of this marker if your total IgA is low.

A positive on this marker with a positive standard test, a compatible genetic profile, and gut damage on biopsy builds a strong case for celiac disease. A positive on this marker alone, with normal standard tests, usually warrants watchful waiting and a conversation with a gastroenterologist rather than immediate action. Whatever you do, do not remove gluten before your workup is complete, because doing so can erase the very signal these tests need to find. When results are discordant or your total IgA is low, a specialist should decide whether genetic testing (HLA-DQ2/DQ8) or a biopsy is the right next step.